Soft-tissue sarcoma (STS) is a rare and heterogeneous group of tumours that comprise
approximately 1% of all adult cancers, and encompass over 50 different subtypes. These …

Genomic-based precision medicine has not only improved tumour therapy but has also
shown its weaknesses. Genomic profiling and mutation analysis have identified alterations …

Sarcomas are rare malignancies with over 100 distinct histological subtypes. Their rarity and
heterogeneity pose significant challenges to identifying effective therapies, and approved …

Molecularly targeted cancer therapy has rapidly changed the landscape of oncologic care,
often improving patients' prognosis without causing as substantial a quality-of-life decrement …

Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence
rate and mortality. Over the past decades, less progress has been achieved. Surgical …

Background The most appropriate design of Phase-II trials evaluating new therapies in
osteosarcoma remains poorly defined. Objective To study consistency in phase-II clinical …

Angiosarcomas are rare malignant tumors with a heterogeneous clinical presentation and
generally poor prognosis. It has been difficult to establish consistent molecular …

Sarcomas are rare and complex malignancies that have been associated with a poor
prognostic outcome. Over the last few decades, traditional treatment with surgery and/or …

Soft tissue sarcoma (STS) are a broad group of rare tumors. Cornerstone of treatment is
surgery. Complementary radiotherapy is recommended in high-risk STS arising from …

Background/Aim: Osteosarcoma is a rare but recalcitrant type of bone cancer. To discover
an effective therapy for osteosarcoma, we used a patient-derived orthotopic xenograft …